Deflazacort - Providing crucial medicine for DMD Patients
Over the past few years many Doctors in the US, specialising in Child Neurology and Neuromuscular Disorders, have been prescribing Deflazacort for their patients with Duchenne’s Muscular Dystrophy. Deflazacort is a Glucocortoid (a class of steroid hormone) used as an anti-inflammatory and immunosuppressant.
As the product is still unlicensed in the US, Masters continues to work closely with several of these prescribing Doctors, in supplying Deflazacort to their patients.
Masters also continues to support the PPMD (Parent Project Muscular Dystrophy) with Annual Sponsorship, and since supplying Deflazacort to patients in the US, has established a strong relationship with the patients’ families.
More information on the PPMD can be found here: http://community.parentprojectmd.org
Deflazacort Treatment is available in the following strengths and packs:
Deflazacort 6mg Tablets - Pack of 20
Calcort 6mg Tablets - Pack of 60
Deflazacort 30mg Tablets - Pack of 10
Zamene Drops 22.75mg/ml - 13ml Pack
If you would like to place an order for Deflazacort, then please click here, and you will be taken directly to our ordering system.
Vetoryl – Named Patient Supply for the Animal Patient
Masters has developed and built Dechra’s global Named Patient Supply for Vetoryl (trilostane), Dechra’s treatment for Cushing’s syndrome in dogs.
In 2004, Masters started supplying Vetoryl on a named patient basis to pet owners, veterinary hospitals and clinics in the US and licensed vets in the EU. The move was in response to several enquiries from pet owners in US asking whether we could obtain trilostane.
Masters generated more than $1 million in revenue for Dechra’s US business before local registration in January 2009. We continue to supply the 120mg version in the US, following EU registration and US registration of the 30mg and 60mg presentations.
In February 2008, we initiated a partnership with Endocrinovet in Sao Paulo, Brazil, to supply Vetoryl to Brazilian pet owners on a named patient basis. We have now expanded the business to Far East Asia, where demand for the treatment is continuing to grow.